Last reviewed · How we verify
ID-LV305
At a glance
| Generic name | ID-LV305 |
|---|---|
| Sponsor | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (PHASE1)
- Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) (PHASE2)
- Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ID-LV305 CI brief — competitive landscape report
- ID-LV305 updates RSS · CI watch RSS
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) portfolio CI